• Envue Medical entered a committed equity facility allowing sales of up to USD 50 million of common stock to an institutional investor.
• Company controls timing and size of sales, subject to conditions including an effective resale registration statement for the investor.
• Purchase price set at 90% of the lowest VWAP over the three trading days before the purchase date.
• 40% of net proceeds earmarked to redeem Series X Preferred Stock until fully redeemed; remaining proceeds for working capital.
• Facility runs through the first day of the month following 36 months from commencement; company can terminate with five trading days’ notice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envue Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037254), on August 12, 2026, and is solely responsible for the information contained therein.